# Andreas Lundqvist

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 140 papers | 6,061 citations | 87888<br>38 h-index | 76900<br>74 g-index |
| 142 all docs | 142 docs citations | 142 times ranked | 9315 citing authors |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 1 | Engineered NK Cells Against Cancer and Their Potential Applications Beyond. Frontiers in Immunology, 2022, 13, 825979. | 4.8 | 14 |
| 2 | A<sub>2B</sub>adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models. , 2022, 10, e004592. | | 8 |
| 3 | Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress. , 2022, 10, e004458. | | 18 |
| 4 | Phosphodiesterase 4A confers resistance to PGE2â€mediated suppression in CD25<sup>+</sup>/CD54<sup>+</sup> NK cells. EMBO Reports, 2021, 22, e51329. | 4.5 | 8 |
| 5 | Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis. Cells, 2021, 10, 353. | 4.1 | 6 |
| 6 | Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3155-3166. | 4.2 | 13 |
| 7 | CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. Cancers, 2021, 13, 1175. | 3.7 | 2 |
| 8 | B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion. Frontiers in Immunology, 2021, 12, 682627. | 4.8 | 7 |
| 9 | Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 718844. | 4.8 | 1 |
| 10 | Interleukinâ€33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophageâ€Mediated Shedding Mechanism. Advanced Science, 2021, 8, 2101029. | 11.2 | 20 |
| 11 | Interleukinâ€33 is a Novel Immunosuppressor that Protects Cancer Cells from TIL Killing by a Macrophageâ€Mediated Shedding Mechanism (Adv. Sci. 21/2021). Advanced Science, 2021, 8, . | 11.2 | 1 |
| 12 | Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy. Cancers, 2020, 12, 3586. | 3.7 | 75 |
| 13 | Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. OncoImmunology, 2020, 9, 1792058. | 4.6 | 30 |
| 14 | Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22910-22919. | 7.1 | 32 |
| 15 | PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates. OncoImmunology, 2020, 9, 1786888. | 4.6 | 29 |
| 16 | Genetically modified immune cells targeting tumor antigens. , 2020, 214, 107603. | | 17 |
| 17 | The Multifaceted Roles of CXCL9 Within the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1231, 45-51. | 1.6 | 29 |
| 18 | CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. Journal of Clinical Investigation, 2020, 130, 1185-1198. | 8.2 | 139 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells. Journal of Clinical Investigation, 2020, 130, 5508-5522. | 8.2 | 52 |
| 20 | Sarcoma Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 319-348. | 1.6 | 5 |
| 21 | Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma. Scientific Reports, 2019, 9, 12150. | 3.3 | 54 |
| 22 | Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers, 2019, 11, 1040. | 3.7 | 40 |
| 23 | Evaluation of Breast Cancer and Melanoma Metastasis in Syngeneic Mouse Models. Methods in Molecular Biology, 2019, 1913, 197-206. | 0.9 | 1 |
| 24 | Strategies and Techniques for NK Cell Phenotyping. Methods in Molecular Biology, 2019, 2032, 105-114. | 0.9 | 0 |
| 25 | Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples. Blood, 2019, 134, 1848-1848. | 1.4 | 0 |
| 26 | The Role of CXC Chemokine Receptors 1â€"4 on Immune Cells in the Tumor Microenvironment. Frontiers in Immunology, 2018, 9, 2159. | 4.8 | 158 |
| 27 | Acoustic formation of multicellular tumor spheroids enabling on-chip functional and structural imaging. Lab on A Chip, 2018, 18, 2466-2476. | 6.0 | 51 |
| 28 | Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma. Cancer Immunology Research, 2018, 6, 1417-1425. | 3.4 | 25 |
| 29 | Abstract A77: Cripto-1 vaccination elicits protective immune response to metastatic breast cancer and breast cancer stem cells. , 2018, , . | | 0 |
| 30 | â€œMarkers and function of human NK cells in normal and pathological conditions.â€ Cytometry Part B - Clinical Cytometry, 2017, 92, 98-99. | 1.5 | 2 |
| 31 | Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon-Î³ and multiple toll-like receptor agonists. Cancer Immunology, Immunotherapy, 2017, 66, 1333-1344. | 4.2 | 31 |
| 32 | Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. OncoImmunology, 2017, 6, e1338238. | 4.6 | 19 |
| 33 | Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. , 2017, 5, 73. | | 106 |
| 34 | Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 2017, 8, 21539-21553. | 1.8 | 103 |
| 35 | Cripto-1 vaccination elicits protective immunity against metastatic melanoma. OncoImmunology, 2016, 5, e1128613. | 4.6 | 21 |
| 36 | IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood, 2016, 128, 1475-1489. | 1.4 | 136 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis. OncoImmunology, 2016, 5, e1052213. | 4.6 | 51 |
| 38 | Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. Human Vaccines and Immunotherapeutics, 2016, 12, 607-611. | 3.3 | 38 |
| 39 | Abstract B071: Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN-Î³. , 2016, , . | | 0 |
| 40 | Dendritic cell regulation of NKâ€cell responses involves lymphotoxinâ€Î±, ILâ€12, and TGFâ€Î². European Journal of Immunology, 2015, 45, 1783-1793. | 2.9 | 34 |
| 41 | Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0139809. | 2.5 | 26 |
| 42 | CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunology, Immunotherapy, 2015, 64, 225-235. | 4.2 | 136 |
| 43 | T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. Cancer Drug Discovery and Development, 2015, , 211-229. | 0.4 | 0 |
| 44 | Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System. International Journal of Molecular Sciences, 2014, 15, 18557-18573. | 4.1 | 18 |
| 45 | Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cellâ€"Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells. Clinical Cancer Research, 2014, 20, 5733-5744. | 7.0 | 47 |
| 46 | Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients. Immunobiology, 2014, 219, 189-197. | 1.9 | 7 |
| 47 | Gap Junction Intercellular Communications Regulate NK Cell Activation and Modulate NK Cytotoxic Capacity. Journal of Immunology, 2014, 192, 1313-1319. | 0.8 | 42 |
| 48 | Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. Clinical Cancer Research, 2014, 20, 4096-4106. | 7.0 | 230 |
| 49 | Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta. Blood, 2014, 124, 4140-4140. | 1.4 | 0 |
| 50 | Doxorubicin sensitizes human tumor cells to NK cellâ€and Tâ€cellâ€mediated killing by augmented TRAIL receptor signaling. International Journal of Cancer, 2013, 133, 1643-1652. | 5.1 | 54 |
| 51 | HLA-dependent tumour development: a role for tumour associate macrophages?. Journal of Translational Medicine, 2013, 11, 247. | 4.4 | 55 |
| 52 | Activated monocytes augment <scp>TRAIL</scp>â€mediated cytotoxicity by human <scp>NK</scp> cells through release of <scp>IFN</scp>â€Î³. European Journal of Immunology, 2013, 43, 249-257. | 2.9 | 23 |
| 53 | A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. Cancer Immunology, Immunotherapy, 2013, 62, 1359-1368. | 4.2 | 27 |
| 54 | Differences in the Phenotype, Cytokine Gene Expression Profiles, and In Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with G-CSF. Journal of Immunology, 2013, 191, 6241-6249. | 0.8 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2â€"Dependent Mechanisms. Cancer Research, 2013, 73, 3877-3887. | 0.9 | 160 |
| 56 | Abstract A63: Melanoma-educated CD14+ monocytes become myeloid-derived suppressor cell-like and are potent inhibitors of autologous T cells through Cox-2 production and STAT-3 signaling.. , 2013, , . | | 2 |
| 57 | Abstract A15: IFN-gamma-inducible-protein-10 stimulates intratumoral infiltration of adoptively transferred human NK cells in a melanoma xenograft mouse model.. , 2013, , . | | 0 |
| 58 | Opposing consequences of signaling through EGF family members. OncoImmunology, 2012, 1, 1200-1201. | 4.6 | 2 |
| 59 | Stereotactic Ablative Radio Therapy (SABR) followed by immunotherapy a challenge for individualized treatment of metastatic solid tumours. Journal of Translational Medicine, 2012, 10, 104. | 4.4 | 11 |
| 60 | Cancer classification using the Immunoscore: a worldwide task force. Journal of Translational Medicine, 2012, 10, 205. | 4.4 | 676 |
| 61 | HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. Journal of Immunology, 2012, 188, 2136-2145. | 0.8 | 51 |
| 62 | Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 2011, 13, 269-278. | 0.7 | 67 |
| 63 | Unlicensed natural born killers. Blood, 2011, 117, 6974-6975. | 1.4 | 1 |
| 64 | A Phase I Trial of Adoptively Transferred Ex-Vivo Expanded Autologous Natural Killer (NK) Cells Following Treatment with Bortezomib to Sensitize Tumors to NK Cell Cytotoxicity. Blood, 2011, 118, 1001-1001. | 1.4 | 3 |
| 65 | Optimizing Lentiviral Transduction of Human Natural Killer Cells. Blood, 2011, 118, 4714-4714. | 1.4 | 37 |
| 66 | Bortezomib Treatment to Potentiate the Anti-tumor Immunity of Ex-vivo Expanded Adoptively Infused Autologous Natural Killer Cells. Journal of Cancer, 2011, 2, 383-385. | 2.5 | 66 |
| 67 | Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood, 2010, 116, 2858-2859. | 1.4 | 28 |
| 68 | Major Histocompatibility Complex-I Expression on Embryonic Stem Cell-Derived Vascular Progenitor Cells Is Critical for Syngeneic Transplant Survival. Stem Cells, 2010, 28, 1465-1475. | 3.2 | 21 |
| 69 | Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells. Journal of Immunology, 2010, 184, 1139-1142. | 0.8 | 29 |
| 70 | Abstract 1271: <i>In vitro</i> expanded natural killer (NK) cells are more susceptible to Fas-mediated apoptosis compared to fresh and overnight IL-2 activated NK cells. Cancer Research, 2010, 70, 1271-1271. | 0.9 | 2 |
| 71 | Solid tumors in adults. , 2009, , 137-145. | | 0 |
| 72 | Natural Killer (NK) Cells Are Resistant to the Apoptotic Effects of Corticosteroids Compared to T Cells: Implications for Adoptive NK Cell Therapy Following Allogeneic HCT. Biology of Blood and Marrow Transplantation, 2009, 15, 9-10. | 2.0 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Bortezomib Treatment Of Primitive Quiescent CD34+ Cell S In Chronic Myeloid Leukemia Enhances Targeting By In Vitro Expanded Allogeneic Natural Killer Cell S. Biology of Blood and Marrow Transplantation, 2009, 15, 126-127. | 2.0 | 4 |
| 74 | Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy, 2009, 11, 341-355. | 0.7 | 257 |
| 75 | Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood, 2009, 113, 875-882. | 1.4 | 61 |
| 76 | Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood, 2009, 113, 6120-6127. | 1.4 | 90 |
| 77 | Adoptive Infusion of Ex Vivo Expanded Autologous Natural Killer (NK) Cells in Cancer Patients Treated with Bortezomib to Sensitize to NK-TRAIL Cytotoxicity.. Blood, 2009, 114, 4080-4080. | 1.4 | 2 |
| 78 | In Vitro Expanded NK Cells Have Increased Natural Cytotoxity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 â€"Activated NK Cells.. Blood, 2009, 114, 463-463. | 1.4 | 4 |
| 79 | Adoptive Transfer of Natural Killer (NK) Cells to Prevent Gvhd and Enhance GVT Effects After Allogeneic Hematopoietic Cell Transplantation (HCT): The Timing of Donor NK Cell Infusions Critically Impacts Transplant Outcome.. Blood, 2009, 114, 786-786. | 1.4 | 1 |
| 80 | Natural killer cell immunotherapy for cancer: a new hope. Cytotherapy, 2008, 10, 775-783. | 0.7 | 66 |
| 81 | Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. Journal of Clinical Investigation, 2008, 118, 1099-109. | 8.2 | 118 |
| 82 | Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. Journal of Clinical Investigation, 2008, 118, 1584-1584. | 8.2 | 135 |
| 83 | Adoptively-Infused NK Cells Maintain Their Antitumor Effects in Vivo in the Presence of CyclosporineA (CSA). Blood, 2008, 112, 2563-2563. | 1.4 | 10 |
| 84 | A Rhesus Macaque Model to Optimize Adoptive NK Cell Therapy. Blood, 2008, 112, 3905-3905. | 1.4 | 0 |
| 85 | Lentiviral Transduction of Ex Vivo Expanded Natural Killer Cells with a CD19 Chimeric Antigen Receptor Induces Cytotoxicity against Resistant B Cell Malignancies. Blood, 2008, 112, 3540-3540. | 1.4 | 0 |
| 86 | A Highly Efficient Method to Expand CD3-CD56+ NK Cells from Cord Blood Segments. Blood, 2008, 112, 3902-3902. | 1.4 | 0 |
| 87 | Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood, 2007, 109, 3603-3606. | 1.4 | 88 |
| 88 | Nephrotic syndrome associated with thrombotic microangiopathy following allogeneic stem cell transplantation for myelodysplastic syndrome ? response to Nakamura et al. British Journal of Haematology, 2007, 136, 859-860. | 2.5 | 0 |
| 89 | Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.. Blood, 2007, 110, 1786-1786. | 1.4 | 2 |
| 90 | In Vitro-Expanded NK Cells Have Increased TRAIL and NKG2D Expression and Enhanced TRAIL-Mediated Tumor Cytotoxicity Compared to Non-Expanded NK Cells.. Blood, 2007, 110, 2744-2744. | 1.4 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.. Blood, 2007, 110, 3277-3277. | 1.4 | 3 |
| 92 | Cyclosporine A (CSA) Significantly Reduces the Cytotoxic Effects of In Vitro Expanded NK Cells: Implications for Adoptive NK Cell Therapy in the Setting of Allogeneic Hematopoietic Stem Cell Transplantation (HCT).. Blood, 2007, 110, 4899-4899. | 1.4 | 2 |
| 93 | Primitive Quiescent CD34+ Cells in Chronic Myeloid Leukemia Are Targeted by In Vitro Expanded Allogeneic Natural Killer Cells, Which Are Functionally Enhanced by Bortezomib Treatment.. Blood, 2007, 110, 1008-1008. | 1.4 | 0 |
| 94 | The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.. Blood, 2007, 110, 1789-1789. | 1.4 | 0 |
| 95 | Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. British Journal of Haematology, 2006, 133, 305-314. | 2.5 | 102 |
| 96 | Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 2006, 34, 796-801. | 0.4 | 74 |
| 97 | Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factorâ€"Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity. Cancer Research, 2006, 66, 7317-7325. | 0.9 | 146 |
| 98 | Impact of KIR and HLA Genotypes on Outcome in Nonmyeloablative Hematopoietic Cell Transplantation (HCT) Using HLA Matched Related Donors.. Blood, 2006, 108, 323-323. | 1.4 | 5 |
| 99 | In Vitro and In Vivo Sensitization of Malignant Cells to Autologous Natural Killer Cell Cytotoxicity Following Exposure to Bortezomib.. Blood, 2006, 108, 925-925. | 1.4 | 1 |
| 100 | Adoptive Infusion of Alloreactive Donor NK Cells Reduces GVHD, Mediates Anti-Tumor Effects and Prolongs Survival in Recipients of MHC-Matched Hematopoietic Cell Transplantation.. Blood, 2006, 108, 3233-3233. | 1.4 | 0 |
| 101 | Pre-Transplant T-Cell Lymphopenia Accelerates Early Donor T-Cell and Myeloid Chimerism but Is Not Required for Full Donor Lymphohematopoietic Engraftment or To Prevent Graft Rejection Following Nonmyeloablative Hematopoietic Cell Transplantation (NST).. Blood, 2006, 108, 2981-2981. | 1.4 | 0 |
| 102 | Mature Dendritic Cells Induce Tumor-Specific Type 1 Regulatory T Cells. Journal of Immunotherapy, 2005, 28, 229-235. | 2.4 | 20 |
| 103 | Allogeneic Hematopoietic Cell Transplantation as Immunotherapy for Solid Tumors. Journal of Immunotherapy, 2005, 28, 281-288. | 2.4 | 38 |
| 104 | Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. British Journal of Haematology, 2005, 128, 668-675. | 2.5 | 102 |
| 105 | Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2005, 131, 74-79. | 2.5 | 73 |
| 106 | Effects of human plasma proteins on maturation of monocyte-derived dendritic cells. Immunology Letters, 2005, 100, 113-119. | 2.5 | 16 |
| 107 | Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncology, The, 2005, 6, 809-812. | 10.7 | 13 |
| 108 | Adoptive Infusion of Allogeneic KIR Ligand Mismatched NK Cells Reduce GVHD in an MHC Matched Allogeneic Stem Cell Transplantation Model.. Blood, 2005, 106, 1310-1310. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | AMD3100 Mobilized Apheresis Products Are Rich in T-Cells That Do Not Undergo a Th-2 Type Cytokine Polarization: Implications for Allografting.. Blood, 2005, 106, 296-296. | 1.4 | 38 |
| 110 | Allograft Cell Content and GVHD Differ in Murine Recipients of AMD3100 Versus G-CSF Mobilized Peripheral Blood Stem Cells.. Blood, 2005, 106, 3108-3108. | 1.4 | 1 |
| 111 | A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. British Journal of Cancer, 2004, 91, 688-694. | 6.4 | 172 |
| 112 | Correlation between HLA-A2 Gene Frequency, Latitude, Ovarian and Prostate Cancer Mortality Rates. Medical Oncology, 2004, 21, 49-52. | 2.5 | 28 |
| 113 | Allogeneic Tumorâ€"Dendritic Cell Fusion Vaccines for Generation of Broad Prostate Cancer T-Cell Responses. Medical Oncology, 2004, 21, 155-166. | 2.5 | 18 |
| 114 | Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy, 2004, 6, 363-371. | 0.7 | 20 |
| 115 | Overexpression and functional characterisation of the human melanocortin 4 receptor in Sf9 cells. Protein Expression and Purification, 2004, 37, 455-461. | 1.3 | 9 |
| 116 | Effects of pH, salt and time on ligand binding properties of overexpressed melanocortin 4 receptor. Journal of Proteomics, 2004, 58, 195-205. | 2.4 | 1 |
| 117 | A Detailed Phenotypic Analysis Using Six Color Flow Cytometry of Lymphocyte Subsets Mobilized with AMD3100 Compared to G-CSF.. Blood, 2004, 104, 408-408. | 1.4 | 2 |
| 118 | Potent Graft-Versus-Renal Cell Carcinoma (RCC) Effects in a Murine Minor Histocompatibility Antigen (mHa)-Mismatched Allogeneic Transplant Model.. Blood, 2004, 104, 4982-4982. | 1.4 | 0 |
| 119 | Complex Alterations in Serum Cytokines and Increased Il-4 Levels Characterize Patients Developing Chronic Thrombocytopenia after Allogeneic Hematopoietic Cell Transplantation.. Blood, 2004, 104, 4985-4985. | 1.4 | 0 |
| 120 | The Graft-vs-Host Hematopoietic Effect Generated after Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Cures Patients with Severe PNH.. Blood, 2004, 104, 811-811. | 1.4 | 0 |
| 121 | Cd8+ T-Cells Specifically Cytotoxic to Renal Cell Carcinoma (RCC) Cells Can Be Isolated from Patients with Regressing Metastatic Kidney Cancer after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (NMHCT).. Blood, 2004, 104, 4984-4984. | 1.4 | 0 |
| 122 | Recombinant Adenovirus Vector Activates and Protects Human Monocyte-Derived Dendritic Cells from Apoptosis. Human Gene Therapy, 2002, 13, 1541-1549. | 2.7 | 26 |
| 123 | Nonviral and Viral Gene Transfer Into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection. Journal of Immunotherapy, 2002, 25, 445-454. | 2.4 | 40 |
| 124 | Heat-shock proteins as activators of the innate immune system. Trends in Immunology, 2002, 23, 130-135. | 6.8 | 534 |
| 125 | Mature dendritic cells are protected from Fas/CD95-mediated apoptosis by upregulation of Bcl-X L. Cancer Immunology, Immunotherapy, 2002, 51, 139-144. | 4.2 | 55 |
| 126 | Immobilized-biomembrane affinity chromatography for binding studies of membrane proteins. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 768, 31-40. | 2.3 | 35 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker. British Journal of Cancer, 2002, 87, 414-422. | 6.4 | 106 |
| 128 | Gene-Modified Dendritic Cells for Immunotherapy Against Cancer. Medical Oncology, 2002, 19, 197-212. | 2.5 | 11 |
| 129 | Advantages of quantitative affinity chromatography for the analysis of solute interaction with membrane proteins. Journal of Proteomics, 2001, 49, 507-521. | 2.4 | 16 |
| 130 | Conversion between two cytochalasin B-binding states of the human GLUT1 glucose transporter. FEBS Journal, 2000, 267, 6875-6882. | 0.2 | 19 |
| 131 | Biomembrane-affinity centrifugal analyses of solute interactions with membrane proteins. Journal of Chromatography A, 1999, 852, 93-96. | 3.7 | 5 |
| 132 | Freezeâ€"thaw immobilization of liposomes in chromatographic gel beads: evaluation by confocal microscopy and effects of freezing rate. , 1998, 11, 52-57. | | 18 |
| 133 | Biomembrane affinity chromatographic analysis of nitrobenzylthioinosine binding to the reconstituted human red cell nucleoside transporter. , 1998, 11, 58-61. | | 10 |
| 134 | Biomembrane affinity chromatographic analysis of inhibitor binding to the human red cell nucleoside transporter in immobilized cells, vesicles and proteoliposomes. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1371, 1-4. | 2.6 | 15 |
| 135 | Immobilization of human red cells in gel particles for chromatographic activity studies of the glucose transporter Glut1. Biochimica Et Biophysica Acta - Biomembranes, 1997, 1325, 91-98. | 2.6 | 31 |
| 136 | Frontal affinity chromatographic analysis of membrane protein reconstitution. Materials Science and Engineering C, 1997, 4, 221-226. | 7.3 | 14 |
| 137 | Chromatography on cells and biomolecular assemblies. Biomedical Applications, 1997, 699, 209-220. | 1.7 | 32 |
| 138 | Glucose affinity for the glucose transporter Glut1 in native or reconstituted lipid bilayers. Journal of Chromatography A, 1997, 776, 87-91. | 3.7 | 19 |
| 139 | d-Glucose, forskolin and cytochalasin B affinities for the glucose transporter Glut1. Journal of Chromatography A, 1997, 776, 81-86. | 3.7 | 21 |
| 140 | Immobilized Membrane Vesicle or Proteoliposome Affinity Chromatography. Frontal Analysis of Interactions of Cytochalasin B andd-Glucose with the Human Red Cell Glucose Transporterâ€. Biochemistry, 1996, 35, 12141-12145. | 2.5 | 94 |